Table 1.
Demographics | ||||
---|---|---|---|---|
Characteristics | Overall | Breast cancer N=8 |
Lymphoma/leukemia n=11 | Other solid tumors n=8 |
Age (years) | 47.1 ±13.9 | 49.2 ±12.3 | 44.7 ±14.3 | 48.2 ±14.2 |
Sex, % female | 67% | 100% | 36% | 75% |
Race % Caucasian |
67% | 63% | 73% | 63% |
% African-American | 26% | 25% | 18% | 37% |
% Asian-American | 4% | 12% | - | - |
% Hispanic | 4% | - | 9% | - |
Lab features at presentation (Median) | ||||
AST (IU/L) | 963 (125–7197) | 948 (370–5706) | 2466 (125–7197) | 367 (142–3266) |
ALT (IU/L) | 673 (46–6904) | 466 (46–2439) | 1161 (112–6904) | 427 (141–1677) |
Alkaline phosphatase (IU/L) | 393 (110–3301) | 547 (166–902) | 280 (110–2043) | 367 (254–3301) |
Total bilirubin (mg/dL) | 12.3 (1.3–30.7) | 12.7 (1.3–30.7) | 12.2 (5.1–26.0) | 14.4 (2.7–27.0) |
Creatinine (mg/dL) | 1.9 (0.5–5.6) | 1.8 (0.5–3.3) | 2.1 (0.6–5.6) | 1.7 (0.7–5.4) |
INR | 2.1 (1.4–3.9) | 2.2 (1.6–3.9) | 2.0 (1.4 –3.1) | 2.0 (1.6–3.4) |
WBC (× 103/mm3) | 12.0 (1.8–47.6) | 13.3 (8.5–21.9) | 8.8 (1.8–47.6) | 13.5 (5.8–29.1) |
Hgb (g/dL) | 9.7 (7.4–16.0) | 10.8 (7.5–14.8) | 8.6 (7.4 –16.0) | 9.5 (7.5–12.5) |
Plts × 103 uL | 106 (11–303) | 101 (11–259) | 74 (12–141) | 130 (28–303) |
Clinical status at presentation | ||||
% Intubated on arrival | 11% (3/27) | 25% (2/8) | 9% (1/11) | 0% (0/8) |
% Required hemodialysis | 7% (2/27) | - | 9% (1/11) | 12% (1/8) |
% Infected | 4% (1/27) | 12% (1/8) | - | - |
% Grade 3–4 Encephalopathy | 22% (6/27) | 25% (2/8) | 27% (3/11) | 13% (1/8) |
Outcomes | ||||
% Salvage chemotherapy | 11% (3/27) | 13% (1/8) | 9% (1/11) | 13% (1/8) |
% OLT | 7% (2/27) | 0% (0/8) | 9% (1/11) | 13% (1/8) |
% Alive at 3 weeks post-study enrollment | 11% (3/27) | 13% (1/8) | 9% (1/11) | 13% (1/8) |
Median time to death after admission (days) | 10.5 (3–28) | 7 (3–13) | 12 (6–28) | 14 (8–21) |
All laboratory values refer to those noted on admission.
WBC= White blood cell count; INR = International Normalized Ratio; OLT= Orthotopic liver transplant.